Nikolaus, Susanna
Waetzig, Georg H.
Butzin, Sven
Ziolkiewicz, Monika
Al-Massad, Natalie
Thieme, Florian
Lövgren, Ulf
Rasmussen, Birgitte B.
Reinheimer, Torsten M.
Seegert, Dirk
Rosenstiel, Philip
Szymczak, Silke
Schreiber, Stefan http://orcid.org/0000-0003-2254-7771
Funding for this research was provided by:
Ferring Pharmaceuticals
CONARIS Research Institute AG
German Excellence Cluster “Inflammation at Interfaces” (ExC306)
SysINFLAME consortium of the German Ministry of Education and Research (01ZX1306)
Collaborative research center CRC1182 of the German Research Foundation (C2)
SYSCID consortium of the EU Horizon 2020 program (733100)
Article History
Accepted: 29 April 2018
First Online: 11 May 2018
Compliance with ethical standards
:
: GHW and DS are employed by CONARIS Research Institute AG, which has out-licenced its interleukin-6 inhibitor olamkicept to Ferring Pharmaceuticals. UL, BBR and TMR are employed by Ferring Pharmaceuticals. SSc heads the supervisory board of CONARIS. The other authors declare no conflict of interest.
: Ethics approval was granted by the ethics committee of the medical faculty of Kiel University prior to the study (AZ D489/14). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study. The ethical concept of healthcare-embedded biobanking with broad informed consents as implemented in Kiel has recently been described [CitationRef removed].